Alan L Ho
JHU Sidney Kimmel Comprehensive Cancer Center LAO · NRG Oncology · Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alan L Ho as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:47 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05669664 · Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland CancersNational Cancer Institute (NCI) · active not recruiting · Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma · principal investigator
- Ph2NCT05408845 · Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersNRG Oncology · recruiting · Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 · principal investigator
- Ph2NCT04544111 · PDR001 Combination Therapy for Radioiodine-Refractory Thyroid CancerMemorial Sloan Kettering Cancer Center · active not recruiting · Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer · principal investigator
- Ph1NCT04462471 · Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid CancersMemorial Sloan Kettering Cancer Center · completed · Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular · principal investigator
- Ph2NCT02393690 · Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid CancerAcademic and Community Cancer Research United · completed · Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma · principal investigator
- Ph2NCT02152995 · Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid CancerNational Cancer Institute (NCI) · active not recruiting · Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma · principal investigator
- Early Ph1NCT02145143 · Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot StudyMemorial Sloan Kettering Cancer Center · completed · Thyroid Carcinoma · principal investigator
- Ph2NCT01558661 · Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic CarcinomaMemorial Sloan Kettering Cancer Center · completed · Adenoid Cystic Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 50 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A Phase 2 Trial of Darolutamide plus Leuprolide Acetate in Advanced Androgen Receptor Positive Salivary Gland CancerR01FD008542 · FDA · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2026 · $2,583,632 awarded in 2026Same name and institution; not confirmed by an ID
- Phase II trial of avutometinib plus defactinib in RAF dimer-driven thyroid cancersR01FD008181 · FDA · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2024 to 2026 · $216,447 awarded in 2026Same name and institution; not confirmed by an ID
- Improving efficacy of radioiodine treatment of thyroid cancerR01CA249663 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2021 to 2025 · $471,416 awarded in 2025Same name and institution; not confirmed by an ID
- Identifying and targeting neoantigens in aggressive salivary carcinomasR01DE027738 · NIDCR · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2018 to 2022 · $455,430 awarded in 2022Same name and institution; not confirmed by an ID
- Targeting MEK to Restore Radioiodine Efficacy for RAI-Refractory Thyroid CancerR01CA184724 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2015 to 2017 · $620,308 awarded in 2017Grant number is on one of their registry trials
- Targeting the Oncogenic Transcription Factor c-myb in Adenoid Cystic CarcinomasR01CA166978 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2012 to 2013 · $328,386 awarded in 2013Same name and institution; not confirmed by an ID
- Immunization Against Melanoma Differentiation AntigensR01CA056821 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 1992 to 2012 · $305,986 awarded in 2012Same name and institution; not confirmed by an ID
- Genetic Approaches to Immune AdjuvantsP01CA059350 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 1997 to 2010 · $344,468 awarded in 2010Same name and institution; not confirmed by an ID
- Administrative CoreP01CA033049 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 1985 to 2009 · $452,135 awarded in 2009Same name and institution; not confirmed by an ID
- Immunology Research TrainingT32CA009149 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 1997 to 2005 · $188,052 awarded in 2005Same name and institution; not confirmed by an ID
- CLINICAL STUDIES/TRIALSP01CA047179 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2000 to 2003 · $230,631 awarded in 2003Same name and institution; not confirmed by an ID
- IMMUNOLOGYP30CA008748 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 1998 to 2002 · $157,506 awarded in 2002Grant number is on one of their registry trials
- CLINICAL TRIALS OF MONOCLONAL ANTIBODIES-IMMUNON01CM097609 · NCI · MEMORIAL HOSPITAL FOR CANCER & ALLIED DI · fiscal years 1989 to 1994 · $200,000 awarded in 1994Same name and institution; not confirmed by an ID
- PHASE I TRIAL (FAB1/2 FRAGMENTS OF R24 MELANOMAN01CM047665 · NCI · MEMORIAL HOSPITAL FOR CANCER & ALLIED DI · fiscal years 1985 to 1992Same name and institution; not confirmed by an ID
- SPECIFICITY OF MONOCLONAL ANTIBODIES TO HUMAN CANCERR01CA034079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 1985 · $138,803 awarded in 1985Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- The Johns Hopkins Translational Science Team and Consortium for ETCTN StudiesUM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci, Ryan Gentzler, GLENN LIU, Wells A. Messersmith, Jimmy Ruiz · fiscal years 2016 to 2026Named on NCT05669664
- NRG Oncology Network Group Operations CenterU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2016 to 2026Named on NCT05408845
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2015 to 2026Named on NCT02393690
- Maximizing Effectiveness of Radioiodine Therapy by Inhibiting MAPK SignalingP50CA172012 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JAMES A FAGIN · fiscal years 2015 to 2018Named on NCT02152995
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:47 UTC. The ranking covers the 200 most relevant of 35 PubMed records, and a shared surname and initials can bring in a namesake. All 35 on PubMed
- Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.N Engl J Med · 2013643 citationsRCR 19.6
- Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.J Clin Oncol · 2019186 citationsRCR 8.5
- Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations.J Clin Oncol · 2021178 citationsRCR 9.3
- Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.Lancet Oncol · 2013149 citationsRCR 4.2
- Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma.J Clin Oncol · 202498 citationsRCR 13.3
- A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.Ann Oncol · 201695 citationsRCR 3.8
- 61 citationsRCR 2.4
- A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.Int J Radiat Oncol Biol Phys · 202060 citationsRCR 2.6
- 55 citationsRCR 4.1
- Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).J Clin Oncol · 202254 citationsRCR 4.6